MAGEA3 and neoplasm: Indeed, the fusion of an anti-DEC-205 antibody with a tumor antigen (MAGE-A3 or NY-ESO-1) induces a better activation of the CTL response compared to the tumor antigen alone (administered by electroporation of RNA or by pulse of peptides) [141,142].